Get the Stockscreener App
35.50
2.12%
-0.77
After Hours:
35.54
0.04
+0.11%
Tg Therapeutics Inc stock is traded at $35.50, with a volume of 1.81M.
It is down -2.12% in the last 24 hours and down -1.36% over the past month.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$36.27
Open:
$36.18
24h Volume:
1.81M
Relative Volume:
0.89
Market Cap:
$5.64B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-322.73
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
-2.82%
1M Performance:
-1.36%
6M Performance:
+11.99%
1Y Performance:
+79.66%
1-Day Range:
$35.40
$36.59
1-Week Range:
$35.20
$37.61
52-Week Range:
$16.65
$46.48
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
35.50 | 5.76B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Neutral |
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm - ACCESS Newswire
What is the risk reward ratio of investing in TG Therapeutics Inc. stockEarnings Report Recommendation With Low Risk - jammulinksnews.com
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update - GlobeNewswire
The Play On TG Therapeutics (NASDAQ:TGTX) - Seeking Alpha
Institutional Investors May Overlook TG Therapeutics, Inc.'s (NASDAQ:TGTX) Recent US$613m Market Cap Drop as Long-term Gains Remain Positive - 富途牛牛
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update | TGTX Stock News - GuruFocus
TG Therapeutics Announces Conference Call to Discuss Q2 2025 Results and Business Outlook - Quiver Quantitative
TG Therapeutics CEO to Present Q2 2025 Financial Results and Strategic Outlook - Stock Titan
AI Trend Models Suggest Bounce for TG Therapeutics Inc.AI Based High Gain Watchlist Scanner Shared - metal.it
TG Therapeutics Inc. Stock Fails to Break Resistance Traders ReactAccurate Technical Trend Reversal Picks Detected - metal.it
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release - Yahoo Finance
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm - ACCESS Newswire
Revenues Not Telling The Story For TG Therapeutics, Inc. (NASDAQ:TGTX) - simplywall.st
How strong is TG Therapeutics Inc. company’s balance sheetAccelerate your capital gains today - jammulinksnews.com
What institutional investors are buying TG Therapeutics Inc. stockUnlock your portfolio’s full growth potential - jammulinksnews.com
What are analysts’ price targets for TG Therapeutics Inc. in the next 12 monthsBest Dividend Updates From AI Tools - jammulinksnews.com
How does TG Therapeutics Inc. compare to its industry peersDiscover high-growth stocks for your portfolio - jammulinksnews.com
What catalysts could drive TG Therapeutics Inc. stock higher in 2025Exceptional portfolio growth - jammulinksnews.com
Does TG Therapeutics Inc. stock perform well during market downturnsUnlock expert insights for smarter investing - jammulinksnews.com
Jim Cramer on TG Therapeutics: “You Should Buy the Stock” - MSN
Will TG Therapeutics Inc. stock benefit from interest rate changesSkyrocketing profit margins - jammulinksnews.com
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), TG Therapeutics (TGTX) and Ardelyx (ARDX) - The Globe and Mail
TG Therapeutics Inc. Stock Analysis and ForecastTremendous growth potential - Autocar Professional
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX) - The Globe and Mail
Why TG Therapeutics Inc. stock attracts strong analyst attentionDouble Your Capital Alerts - beatles.ru
Is TG Therapeutics Inc. a good long term investmentPhenomenal wealth increase - Autocar Professional
What analysts say about TG Therapeutics Inc. stockRapid wealth multiplication - jammulinksnews.com
What drives TG Therapeutics Inc. stock priceUnstoppable trading performance - Autocar Professional
How To Trade (TGTX) - news.stocktradersdaily.com
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):